6527.TWO Crystalvue Medical Corporation
- Market cap
- TWD 1.83B
- P/E
- 12.5x
- P/B
- 1.74x
- ROE
- 14.8%
- Dividend yield
- 3.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6527.TWO undervalued?
Graham number6527.TWO trades 1.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Crystalvue Medical Corporation fundamental analysis
No fundamental analysis for Crystalvue Medical Corporation yet.
Crystalvue Medical Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Crystalvue Medical Corporation
Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies. The company was founded in 2009 and is based in Taoyuan City, Taiwan.
Full company profileCrystalvue Medical Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Crystalvue Medical Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 722M | 795M | 824M | 868M | 949M | 812M |
| Gross Profit | 211M | 262M | 267M | 299M | 332M | 326M |
| Operating Income | 88.5M | 125M | 118M | 145M | 181M | 167M |
| EBITDA | - | 170M | 150M | 189M | 197M | 185M |
| Net Income | 77.2M | 115M | 103M | 127M | 147M | 152M |
| EPS | 3.08 | 4.63 | 4.09 | 5.04 | 5.80 | 6.01 |
| Balance Sheet | ||||||
| Total Assets | 939M | 1.01B | 1.08B | 1.18B | 1.30B | 1.36B |
| Total Liabilities | 220M | 237M | 221M | 246M | 267M | 324M |
| Shareholders' Equity | 719M | 776M | 857M | 939M | 1.03B | 1.03B |
| Cash & Short-term Investments | 194M | 177M | 273M | 242M | 132M | 84.0M |
| Cash Flow | ||||||
| Operating Cash Flow | 63.3M | 51.8M | 154M | 153M | 139M | 82.7M |
| Capital Expenditure | 352M | 9.01M | 8.54M | 132M | 185M | 219M |
| Free Cash Flow | -289M | 42.8M | 145M | 21.0M | -46.1M | -136M |
| Ratios | ||||||
| ROE | 10.7% | 14.8% | 12.1% | 13.5% | 14.3% | 14.8% |
| ROA | 8.2% | 11.4% | 9.6% | 10.7% | 11.3% | 11.2% |
| Net Profit Margin | 10.7% | 14.5% | 12.5% | 14.6% | 15.5% | 18.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Crystalvue Medical Corporation dividends
- Dividend yield
- 3.12%
- Forward dividend
- 2.90 TWD
- Payout ratio
- 38.8%
- Ex-dividend date
- Jul 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 57.0M | 2.25 | 38.8% |
| 2024 | TWD 52.3M | 2.07 | 41.1% |
| 2023 | TWD 56.8M | 2.25 | 54.9% |
| 2022 | TWD 46.3M | 1.86 | 40.2% |
| 2021 | TWD 33.4M | 1.33 | 43.3% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1050:1000 on Jul 25, 2023.
Who owns Crystalvue Medical Corporation
- Insiders 48.29%
- Institutions 0.00%
- Public & others 51.71%
- Shares outstanding 25.3M
- Free float 14.7M
Crystalvue Medical Corporation company profile
- Company name
- Crystalvue Medical Corporation
- Ticker
- 6527.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Fiscal year end
- December
- Address
- No.116, Zhongshan Road, Taoyuan City, Taiwan, 330
- Phone
- 886 3 360 7711
- Website
- crystalvue.com.tw
About Crystalvue Medical Corporation
Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies. The company was founded in 2009 and is based in Taoyuan City, Taiwan.
Crystalvue Medical Corporation management
1- Zhong Ping ZhuangGM & Director